Three clinically relevant biological BC subtypes have been defined: Estrogen/Progesterone Receptor positive (ER+/PR+), Human Epidermal growth factor Receptor 2 amplified (HER2+) and triple negative (TNBC; i.e., ER−/PR-/HER2−) BC [13]. This evidence concerns the gene ERBB2 and breast cancer.